AbbVie Inc.
ABBVAbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000.
Drugs in Pipeline
187
Phase 3 Programs
116
Upcoming Catalysts
40
Next Catalyst
Mar 15, 2026
5wMarket Overview
Stock performance and market intelligence
40 upcoming, 1 past
Azacitidine Phase 3 Results Expected
Primary completion for Azacitidine trial (NCT04401748) in Myelodysplastic Syndrome (MDS)
SourceVenetoclax Phase 3 Results Expected
Primary completion for Venetoclax trial (NCT03844048) in Chronic Lymphocytic Leukemia
SourceOnabotulinumtoxinA Phase 3 Results Expected
Primary completion for OnabotulinumtoxinA trial (NCT06794866) in Forehead Lines
SourcePlacebo Phase 3 Results Expected
Primary completion for Placebo trial (NCT06794866) in Forehead Lines
SourceABBV-951 Phase 3 Results Expected
Primary completion for ABBV-951 trial (NCT04379050) in Parkinson's Disease (PD)
SourceRisankizumab IV Phase 3 Results Expected
Primary completion for Risankizumab IV trial (NCT03105102) in Crohn's Disease
SourceUbrogepant Phase 3 Results Expected
Primary completion for Ubrogepant trial (NCT05125302) in Migraine
SourceRisankizumab SC Phase 3 Results Expected
Primary completion for Risankizumab SC trial (NCT03105102) in Crohn's Disease
SourceMirvetuximab Soravtansine Phase 2 Results Expected
Primary completion for Mirvetuximab Soravtansine trial (NCT06365853) in Recurrent Ovarian Cancer
SourceTopical Steroid Phase 2 Results Expected
Primary completion for Topical Steroid trial (NCT04567550) in Diabetic Retinopathy (DR)
SourceLubricating Eye Drops Phase 2 Results Expected
Primary completion for Lubricating Eye Drops trial (NCT06365853) in Recurrent Ovarian Cancer
SourceUpadacitinib Phase 3 Results Expected
Primary completion for Upadacitinib trial (NCT05814627) in Rheumatoid Arthritis
SourceTelisotuzumab vedotin Phase 2 Results Expected
Primary completion for Telisotuzumab vedotin trial (NCT03539536) in Non-small Cell Lung Cancer
SourceBimatoprost SR Phase 3 Results Expected
Primary completion for Bimatoprost SR trial (NCT03891446) in Open-Angle Glaucoma
SourceAdalimumab Phase 3 Results Expected
Primary completion for Adalimumab trial (NCT05814627) in Rheumatoid Arthritis
SourceRanibizumab Phase 2 Results Expected
Primary completion for Ranibizumab trial (NCT04514653) in Neovascular Age-Related Macular Degeneration (nAMD)
SourceUpadacitinib 15mg Dose Phase 3 Results Expected
Primary completion for Upadacitinib 15mg Dose trial (NCT06389136) in Atopic Dermatitis
SourceVenetoclax Phase 3 Results Expected
Primary completion for Venetoclax trial (NCT03539744) in Multiple Myeloma
SourcePomalidomide Phase 3 Results Expected
Primary completion for Pomalidomide trial (NCT03539744) in Multiple Myeloma
SourceAdalimumab Phase 3 Results Expected
Primary completion for Adalimumab trial (NCT06100744) in Juvenile Psoriatic Arthritis
SourceRisankizumab Phase 3 Results Expected
Primary completion for Risankizumab trial (NCT06100744) in Juvenile Psoriatic Arthritis
SourceAflibercept (EYLEA®) Phase 3 Results Expected
Primary completion for Aflibercept (EYLEA®) trial (NCT05407636) in AMD
SourceBudigalimab Phase 2 Results Expected
Primary completion for Budigalimab trial (NCT05822752) in Hepatocellular Carcinoma
SourceLenvatinib Phase 2 Results Expected
Primary completion for Lenvatinib trial (NCT05822752) in Hepatocellular Carcinoma
SourceABBV-932 Phase 2 Results Expected
Primary completion for ABBV-932 trial (NCT06846320) in Generalized Anxiety Disorder (GAD)
SourceABBV-444 Phase 3 Results Expected
Primary completion for ABBV-444 trial (NCT07284381) in Dry Eye Disease
SourceLivmoniplimab Phase 2 Results Expected
Primary completion for Livmoniplimab trial (NCT05822752) in Hepatocellular Carcinoma
SourceVenetoclax Phase 2 Results Expected
Primary completion for Venetoclax trial (NCT04895436) in Chronic Lymphocytic Leukemia (CLL)
SourceCarboplatin Phase 2 Results Expected
Primary completion for Carboplatin trial (NCT05456685) in High Grade Ovarian Cancer
SourceObinutuzumab Phase 2 Results Expected
Primary completion for Obinutuzumab trial (NCT04895436) in Chronic Lymphocytic Leukemia (CLL)
SourceMirvetuximab soravtansine Phase 2 Results Expected
Primary completion for Mirvetuximab soravtansine trial (NCT05456685) in High Grade Ovarian Cancer
SourceRanibizumab (LUCENTIS®) Phase 3 Results Expected
Primary completion for Ranibizumab (LUCENTIS®) trial (NCT04704921) in AMD
SourceEluxadoline Phase 2 Results Expected
Primary completion for Eluxadoline trial (NCT03339128) in Irritable Bowel Syndrome
SourceUpadacitinib Phase 3 Results Expected
Primary completion for Upadacitinib trial (NCT05843643) in Systemic Lupus Erythematosus
SourceABBV-400 Phase 2 Results Expected
Primary completion for ABBV-400 trial (NCT06107413) in Unresectable Metastatic Colorectal Cancer
SourcePlacebo Phase 3 Results Expected
Primary completion for Placebo trial (NCT05843643) in Systemic Lupus Erythematosus
SourceLutikizumab Phase 3 Results Expected
Primary completion for Lutikizumab trial (NCT06468228) in Hidradenitis Suppurativa
SourceMEDI0618 Phase 2 Results Expected
Primary completion for MEDI0618 trial (NCT06602479) in Migraine
SourcePlacebo Phase 2 Results Expected
Primary completion for Placebo trial (NCT03339128) in Irritable Bowel Syndrome
SourceUpadacitinib Phase 3 Results Expected
Primary completion for Upadacitinib trial (NCT06701331) in Atopic Dermatitis
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Telisotuzumab Adizutecan
Non-Small Cell Lung Cancer
Cisplatin
Non-squamous Non-small Cell Lung Cancer
AGN-190584
Presbyopia
Topical corticosteroids (TCS)
Atopic Dermatitis
OBV/PTV/r
Chronic Hepatitis C Virus
Botulinum Toxin Type A
Masseter Muscle Prominence
Linaclotide
Functional Constipation (FC)
2 DAA
HCV
Glecaprevir/Pibrentasvir Adult Formulation
Hepatitis C Virus (HCV)
Upadacitinib
Ulcerative Colitis (UC)
ombitasvir/paritaprevir/ritonavir and dasabuvir
Hepatitis C Virus (HCV)
Veliparib
Metastatic Breast Cancer
adalimumab
Pyoderma Gangrenosum
Risankizumab
Crohn's Disease (CD)
Rovalpituzumab tesirine
Small Cell Lung Cancer
ombitasvir/paritaprevir/ritonavir
Hepatitis C Infection
Cariprazine
Depression
ABBV-951
Parkinson's Disease (PD)
BOTOX
Masseter Muscle Prominence
Corticosteroid (CS)
Giant Cell Arteritis (GCA)
Venetoclax
Acute Myeloid Leukemia (AML)
Pegylated Interferon a-2a (PegINF)
Chronic Hepatitis C Infection
ABT-493, ABT-530
Chronic Hepatitis C
Combined Oral Contraceptive
Endometriosis
ABT-530
Chronic Hepatitis C
LUMIGAN
Open-Angle Glaucoma
Pomalidomide
Multiple Myeloma
Optimized antiparkinsonian treatment
Parkinson's Disease (PD)
Lutikizumab
Hidradenitis Suppurativa
Telisotuzumab vedotin
Non-small Cell Lung Cancer
Bimatoprost SR
Open-Angle Glaucoma
Docetaxel
Non Small Cell Lung Cancer
ABT-333
Chronic Hepatitis C Infection
Glecaprevir/Pibrentasvir
Hepatitis C Virus (HCV)
Ubrogepant 100 mg
Migraine
Vedolizumab
Ulcerative Colitis
ABT-493
Chronic Hepatitis C
OnabotulinumtoxinA
Forehead Lines
Bortezomib
Relapsed/Refractory Multiple Myeloma
Dalbavancin
Methicillin-Resistant Staphylococcus Aureus
Mirvetuximab Soravtansine
Epithelial Ovarian Cancer
Abatacept
Rheumatoid Arthritis (RA)
AGN-151586
Glabellar Lines
Atogepant
Chronic Migraine
Sham Bimatoprost SR
Glaucoma, Open-Angle
Estradiol /norethindrone acetate (E2/NETA)
Heavy Menstrual Bleeding
Levodopa-Carbidopa Intestinal Gel (LCIG)
Advanced Parkinson's Disease
Best Available Therapy (BAT)
Myelofibrosis (MF)
Aflibercept (EYLEA®)
AMD
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)
Irritable Bowel Syndrome With Constipation
ABBV-444
Dry Eye Disease
Trifluridine/Tipiracil
Metastatic Colorectal Cancer
Methotrexate
Psoriasis
Armour Thyroid
Hypothyroidism
ABT-874
Plaque Psoriasis
Antidepressant Therapy (ADT)
Major Depressive Disorder
risankizumab IV
Crohn Disease
Open-label Adalimumab
Axial Spondyloarthritis
Sofosbuvir
Chronic Hepatitis C
ombitasvir/paritaprevir/ritonavir, dasabuvir
Chronic Hepatitis C Virus (HCV Infection Genotype 1)
Topiramate
Migraine
Livmoniplimab
Hepatocellular Carcinoma
Budigalimab
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
Cariprazine Flexible Dose
Schizophrenia
ABT-450/r/ABT-267
Hepatitis C Virus Infection
Carfilzomib
Multiple Myeloma
Elotuzumab
Multiple Myeloma
Glecaprevir/Pibrentasvir (GLE/PIB)
Hepatitis C Virus (HCV)
Ruxolitinib
Myelofibrosis (MF)
Cytarabine
Acute Myelogenous Leukemia
Tavapadon
Parkinson Disease
ABT-493 coformulated with ABT-530
Hepatitis C Virus Infection
etanercept
Moderate to Severe Plaque Psoriasis
Bimatoprost (SR)
Open-Angle Glaucoma
Azacitidine
Acute Myeloid Leukemia (AML)
Etentamig
Multiple Myeloma
Acalabrutinib
Chronic Lymphocytic Leukemia
Ustekinumab
Psoriasis
Temozolomide
Glioblastoma
Dupilumab
Atopic Dermatitis
Elagolix
Polycystic Ovary Syndrome
Obinutuzumab
Chronic Lymphocytic Leukemia (CLL)
Carboplatin
High Grade Ovarian Cancer
ABT-450/r/ABT-267, ABT-333
Chronic Hepatitis C Infection
Paricalcitol
Chronic Kidney Disease Stage 3 and 4
Prednisone
Uveitis
ABT-493/ABT-530
Hepatitis C Virus Infection
ribavirin
Chronic Hepatitis C Infection
sofosbuvir (SOF)
Chronic Hepatitis C Virus
Standard of Care
Non-Squamous Non-Small Cell Lung Cancer
Risankizumab SC
Crohn's Disease
Paclitaxel
Metastatic Breast Cancer
Navitoclax
Myelofibrosis (MF)
Tocilizumab
Juvenile Idiopathic Arthritis
Fumaderm
Psoriasis
Fluvoxamine maleate
Obsessive Compulsive Disorder
Atogepant 60 mg
Chronic Migraine
maxacalcitol
Secondary Hyperparathyroidism
Upadacitinib 15mg Dose
Atopic Dermatitis
Optimized Medical Treatment
Advanced Parkinson's Disease
Surabgene Lomparvovec (ABBV-RGX-314)
Neovascular Age-related Macular Degeneration
Ranibizumab (LUCENTIS®)
AMD
ABT-712
Chronic Low Back Pain
Ubrogepant
Migraine
Estradiol/Norethindrone Acetate
Endometriosis
Levodopa-carbidopa intestinal gel
Advanced Parkinson's Disease
Topotecan
Small Cell Lung Cancer
Dasabuvir
Chronic Hepatitis C Infection
Bendamustine
Chronic Lymphocytic Leukemia (CLL)
Prednisolone
Takayasu Arteritis (TAK)
Dexamethasone
Relapsed/Refractory Multiple Myeloma
Palivizumab
Respiratory Syncytial Virus (RSV)
secukinumab
Psoriasis
Telaprevir
Chronic Hepatitis C Infection
Upadacitinib (ABT-494)
Ulcerative Colitis (UC)
Ribavirin (RBV)
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
ABBV-8E12
Alzheimer's Disease
Ibrutinib
Mantle Cell Lymphoma (MCL)
ABT-450
Hepatitis C Virus
Emraclidine 15 mg
Schizophrenia
ABT-267
Chronic Hepatitis C
Ritonavir
Chronic Hepatitis C Infection
ABBV-382
Crohn's Disease
ABT-122
Rheumatoid Arthritis
ABBV-3067
Cystic Fibrosis
Atrasentan
Nephropathy
ABT-981
Erosive Hand Osteoarthritis
ABT-894
Diabetic Neuropathic Pain
Lubricating Eye Drops
Recurrent Ovarian Cancer
ABT-494
Crohn's Disease
Ranibizumab
Neovascular Age-Related Macular Degeneration (nAMD)
ABT-263
Chronic Lymphoid Leukemia
CVL-231 30 mg
Schizophrenia
Emraclidine 10 mg
Schizophrenia
ABBV-CLS-628
Autosomal Dominant Polycystic Kidney Disease
ABBV-400
Unresectable Metastatic Colorectal Cancer
ABT-199 (Main Cohort)
Chronic Lymphocytic Leukemia
Ravagalimab
Rheumatoid Arthritis
CVL-871 1.0 mg
Apathy in Dementia
IMGN632
Acute Myeloid Leukemia
ABT-089
Attention Deficit Hyperactivity Disorder
hydrocodone/acetaminophen extended release
Chronic Low Back Pain
atomoxetine
Attention-Deficit/Hyperactivity Disorder
azacitadine
Non-Hodgkin Lymphoma (NHL)
Elsubrutinib
Systemic Lupus Erythematosus (SLE)
Lenvatinib
Hepatocellular Carcinoma
ABBV-916
Alzheimer's Disease (AD)
ABT-869
Advanced Hepatocellular Carcinoma
ABBV-552
Alzheimer's Disease (AD)
ABBV-6628
Geographic Atrophy
Modified FOLFIRI
Untreated Metastatic Colorectal Cancer
ABT-450/ritonavir (r)
Chronic Hepatitis C
donepezil
Alzheimer's Disease
Depatuxizumab mafodotin
Glioblastoma
Darigabat
Panic Disorder
elezanumab
Multiple Sclerosis (MS)
AGN-151597
Advanced Retinitis Pigmentosa
Gemcitabine
Urothelial Carcinoma
Etoposide
Small Cell Lung Cancer
0.5 mg estradiol / 0.1 mg norethindrone acetate
Heavy Uterine Bleeding
ABBV-3373
Rheumatoid Arthritis (RA)
ABBV-453
Multiple Myeloma
AGN-242428
Dry Eye Disease
CVL-865
Seizures
Eluxadoline
Irritable Bowel Syndrome
ABBV-668
Ulcerative Colitis
Risankizumab 600 mg IV
Crohn Disease
Pneumococcal 13-valent conjugate vaccine (PCV-13)
Rheumatoid Arthritis
Ravagalimab 600 mg
Ulcerative Colitis (UC)
Panitumumab
Metastatic Colorectal Cancer
ABBV-383 (Etentamig)
Immunoglobulin Light Chain (AL) Amyloidosis
AGN-151607
Post-Operative Atrial Fibrillation
Leuprorelin Acetate Depot
Endometriosis
Daratumumab
Multiple Myeloma
ABBV-932
Generalized Anxiety Disorder (GAD)
AGN-193408 SR
Open-angle Glaucoma
ABT-414
Malignant Glioma
MEDI0618
Migraine
ABT-719
Acute Kidney Injury
ABBV-706
Small Cell Lung Cancer
Ombitasvir/ABT-450/Ritonavir
Chronic Hepatitis C
ABT-126
Schizophrenia
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Endometriosis
Topical Steroid
Diabetic Retinopathy (DR)
ABT-199
Acute Myelogenous Leukemia
ABT-072
Hepatitis C Virus Infection
Icalcaprant
Major Depressive Disorder
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Telisotuzumab Adizutecan | Phase 3 | Non-Small Cell Lung Cancer | - |
Cisplatin | Phase 3 | Non-squamous Non-small Cell Lung Cancer | - |
AGN-190584 | Phase 3 | Presbyopia | - |
Topical corticosteroids (TCS) | Phase 3 | Atopic Dermatitis | - |
OBV/PTV/r | Phase 3 | Chronic Hepatitis C Virus | - |
Botulinum Toxin Type A | Phase 3 | Masseter Muscle Prominence | - |
Linaclotide | Phase 3 | Functional Constipation (FC) | - |
2 DAA | Phase 3 | HCV | - |
Glecaprevir/Pibrentasvir Adult Formulation | Phase 3 | Hepatitis C Virus (HCV) | - |
Upadacitinib | Phase 3 | Ulcerative Colitis (UC) | - |
ombitasvir/paritaprevir/ritonavir and dasabuvir | Phase 3 | Hepatitis C Virus (HCV) | - |
Veliparib | Phase 3 | Metastatic Breast Cancer | - |
adalimumab | Phase 3 | Pyoderma Gangrenosum | - |
Risankizumab | Phase 3 | Crohn's Disease (CD) | - |
Rovalpituzumab tesirine | Phase 3 | Small Cell Lung Cancer | - |
ombitasvir/paritaprevir/ritonavir | Phase 3 | Hepatitis C Infection | - |
Cariprazine | Phase 3 | Depression | - |
ABBV-951 | Phase 3 | Parkinson's Disease (PD) | - |
BOTOX | Phase 3 | Masseter Muscle Prominence | - |
Corticosteroid (CS) | Phase 3 | Giant Cell Arteritis (GCA) | - |
Venetoclax | Phase 3 | Acute Myeloid Leukemia (AML) | - |
Pegylated Interferon a-2a (PegINF) | Phase 3 | Chronic Hepatitis C Infection | - |
ABT-493, ABT-530 | Phase 3 | Chronic Hepatitis C | - |
Combined Oral Contraceptive | Phase 3 | Endometriosis | - |
ABT-530 | Phase 3 | Chronic Hepatitis C | - |
LUMIGAN | Phase 3 | Open-Angle Glaucoma | - |
Pomalidomide | Phase 3 | Multiple Myeloma | - |
Optimized antiparkinsonian treatment | Phase 3 | Parkinson's Disease (PD) | - |
Lutikizumab | Phase 3 | Hidradenitis Suppurativa | - |
Telisotuzumab vedotin | Phase 3 | Non-small Cell Lung Cancer | - |
Bimatoprost SR | Phase 3 | Open-Angle Glaucoma | - |
Docetaxel | Phase 3 | Non Small Cell Lung Cancer | - |
ABT-333 | Phase 3 | Chronic Hepatitis C Infection | - |
Glecaprevir/Pibrentasvir | Phase 3 | Hepatitis C Virus (HCV) | - |
Ubrogepant 100 mg | Phase 3 | Migraine | - |
Vedolizumab | Phase 3 | Ulcerative Colitis | - |
ABT-493 | Phase 3 | Chronic Hepatitis C | - |
OnabotulinumtoxinA | Phase 3 | Forehead Lines | - |
Bortezomib | Phase 3 | Relapsed/Refractory Multiple Myeloma | - |
Dalbavancin | Phase 3 | Methicillin-Resistant Staphylococcus Aureus | - |
Mirvetuximab Soravtansine | Phase 3 | Epithelial Ovarian Cancer | - |
Abatacept | Phase 3 | Rheumatoid Arthritis (RA) | - |
AGN-151586 | Phase 3 | Glabellar Lines | - |
Atogepant | Phase 3 | Chronic Migraine | - |
Sham Bimatoprost SR | Phase 3 | Glaucoma, Open-Angle | - |
Estradiol /norethindrone acetate (E2/NETA) | Phase 3 | Heavy Menstrual Bleeding | - |
Levodopa-Carbidopa Intestinal Gel (LCIG) | Phase 3 | Advanced Parkinson's Disease | - |
Best Available Therapy (BAT) | Phase 3 | Myelofibrosis (MF) | - |
Aflibercept (EYLEA®) | Phase 3 | AMD | - |
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) | Phase 3 | Irritable Bowel Syndrome With Constipation | - |
ABBV-444 | Phase 3 | Dry Eye Disease | - |
Trifluridine/Tipiracil | Phase 3 | Metastatic Colorectal Cancer | - |
Methotrexate | Phase 3 | Psoriasis | - |
Armour Thyroid | Phase 3 | Hypothyroidism | - |
ABT-874 | Phase 3 | Plaque Psoriasis | - |
Antidepressant Therapy (ADT) | Phase 3 | Major Depressive Disorder | - |
risankizumab IV | Phase 3 | Crohn Disease | - |
Open-label Adalimumab | Phase 3 | Axial Spondyloarthritis | - |
Sofosbuvir | Phase 3 | Chronic Hepatitis C | - |
ombitasvir/paritaprevir/ritonavir, dasabuvir | Phase 3 | Chronic Hepatitis C Virus (HCV Infection Genotype 1) | - |
Topiramate | Phase 3 | Migraine | - |
Livmoniplimab | Phase 3 | Hepatocellular Carcinoma | - |
Budigalimab | Phase 3 | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma | - |
Cariprazine Flexible Dose | Phase 3 | Schizophrenia | - |
ABT-450/r/ABT-267 | Phase 3 | Hepatitis C Virus Infection | - |
Carfilzomib | Phase 3 | Multiple Myeloma | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - |
Glecaprevir/Pibrentasvir (GLE/PIB) | Phase 3 | Hepatitis C Virus (HCV) | - |
Ruxolitinib | Phase 3 | Myelofibrosis (MF) | - |
Cytarabine | Phase 3 | Acute Myelogenous Leukemia | - |
Tavapadon | Phase 3 | Parkinson Disease | - |
ABT-493 coformulated with ABT-530 | Phase 3 | Hepatitis C Virus Infection | - |
etanercept | Phase 3 | Moderate to Severe Plaque Psoriasis | - |
Bimatoprost (SR) | Phase 3 | Open-Angle Glaucoma | - |
Azacitidine | Phase 3 | Acute Myeloid Leukemia (AML) | - |
Etentamig | Phase 3 | Multiple Myeloma | - |
Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - |
Ustekinumab | Phase 3 | Psoriasis | - |
Temozolomide | Phase 3 | Glioblastoma | - |
Dupilumab | Phase 3 | Atopic Dermatitis | - |
Elagolix | Phase 3 | Polycystic Ovary Syndrome | - |
Obinutuzumab | Phase 3 | Chronic Lymphocytic Leukemia (CLL) | - |
Carboplatin | Phase 3 | High Grade Ovarian Cancer | - |
ABT-450/r/ABT-267, ABT-333 | Phase 3 | Chronic Hepatitis C Infection | - |
Paricalcitol | Phase 3 | Chronic Kidney Disease Stage 3 and 4 | - |
Prednisone | Phase 3 | Uveitis | - |
ABT-493/ABT-530 | Phase 3 | Hepatitis C Virus Infection | - |
ribavirin | Phase 3 | Chronic Hepatitis C Infection | - |
sofosbuvir (SOF) | Phase 3 | Chronic Hepatitis C Virus | - |
Standard of Care | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - |
Risankizumab SC | Phase 3 | Crohn's Disease | - |
Paclitaxel | Phase 3 | Metastatic Breast Cancer | - |
Navitoclax | Phase 3 | Myelofibrosis (MF) | - |
Tocilizumab | Phase 3 | Juvenile Idiopathic Arthritis | - |
Fumaderm | Phase 3 | Psoriasis | - |
Fluvoxamine maleate | Phase 3 | Obsessive Compulsive Disorder | - |
Atogepant 60 mg | Phase 3 | Chronic Migraine | - |
maxacalcitol | Phase 3 | Secondary Hyperparathyroidism | - |
Upadacitinib 15mg Dose | Phase 3 | Atopic Dermatitis | - |
Optimized Medical Treatment | Phase 3 | Advanced Parkinson's Disease | - |
Surabgene Lomparvovec (ABBV-RGX-314) | Phase 3 | Neovascular Age-related Macular Degeneration | - |
Ranibizumab (LUCENTIS®) | Phase 3 | AMD | - |
ABT-712 | Phase 3 | Chronic Low Back Pain | - |
Ubrogepant | Phase 3 | Migraine | - |
Estradiol/Norethindrone Acetate | Phase 3 | Endometriosis | - |
Levodopa-carbidopa intestinal gel | Phase 3 | Advanced Parkinson's Disease | - |
Topotecan | Phase 3 | Small Cell Lung Cancer | - |
Dasabuvir | Phase 3 | Chronic Hepatitis C Infection | - |
Bendamustine | Phase 3 | Chronic Lymphocytic Leukemia (CLL) | - |
Prednisolone | Phase 3 | Takayasu Arteritis (TAK) | - |
Dexamethasone | Phase 3 | Relapsed/Refractory Multiple Myeloma | - |
Palivizumab | Phase 3 | Respiratory Syncytial Virus (RSV) | - |
secukinumab | Phase 3 | Psoriasis | - |
Telaprevir | Phase 3 | Chronic Hepatitis C Infection | - |
Upadacitinib (ABT-494) | Phase 3 | Ulcerative Colitis (UC) | - |
Ribavirin (RBV) | Phase 3 | Chronic Hepatitis C Virus (HCV) Infection Genotype 1 | - |
ABBV-8E12 | Phase 2 | Alzheimer's Disease | - |
Ibrutinib | Phase 2 | Mantle Cell Lymphoma (MCL) | - |
ABT-450 | Phase 2 | Hepatitis C Virus | - |
Emraclidine 15 mg | Phase 2 | Schizophrenia | - |
ABT-267 | Phase 2 | Chronic Hepatitis C | - |
Ritonavir | Phase 2 | Chronic Hepatitis C Infection | - |
ABBV-382 | Phase 2 | Crohn's Disease | - |
ABT-122 | Phase 2 | Rheumatoid Arthritis | - |
ABBV-3067 | Phase 2 | Cystic Fibrosis | - |
Atrasentan | Phase 2 | Nephropathy | - |
ABT-981 | Phase 2 | Erosive Hand Osteoarthritis | - |
ABT-894 | Phase 2 | Diabetic Neuropathic Pain | - |
Lubricating Eye Drops | Phase 2 | Recurrent Ovarian Cancer | - |
ABT-494 | Phase 2 | Crohn's Disease | - |
Ranibizumab | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) | - |
ABT-263 | Phase 2 | Chronic Lymphoid Leukemia | - |
CVL-231 30 mg | Phase 2 | Schizophrenia | - |
Emraclidine 10 mg | Phase 2 | Schizophrenia | - |
ABBV-CLS-628 | Phase 2 | Autosomal Dominant Polycystic Kidney Disease | - |
ABBV-400 | Phase 2 | Unresectable Metastatic Colorectal Cancer | - |
ABT-199 (Main Cohort) | Phase 2 | Chronic Lymphocytic Leukemia | - |
Ravagalimab | Phase 2 | Rheumatoid Arthritis | - |
CVL-871 1.0 mg | Phase 2 | Apathy in Dementia | - |
IMGN632 | Phase 2 | Acute Myeloid Leukemia | - |
ABT-089 | Phase 2 | Attention Deficit Hyperactivity Disorder | - |
hydrocodone/acetaminophen extended release | Phase 2 | Chronic Low Back Pain | - |
atomoxetine | Phase 2 | Attention-Deficit/Hyperactivity Disorder | - |
azacitadine | Phase 2 | Non-Hodgkin Lymphoma (NHL) | - |
Elsubrutinib | Phase 2 | Systemic Lupus Erythematosus (SLE) | - |
Lenvatinib | Phase 2 | Hepatocellular Carcinoma | - |
ABBV-916 | Phase 2 | Alzheimer's Disease (AD) | - |
ABT-869 | Phase 2 | Advanced Hepatocellular Carcinoma | - |
ABBV-552 | Phase 2 | Alzheimer's Disease (AD) | - |
ABBV-6628 | Phase 2 | Geographic Atrophy | - |
Modified FOLFIRI | Phase 2 | Untreated Metastatic Colorectal Cancer | - |
ABT-450/ritonavir (r) | Phase 2 | Chronic Hepatitis C | - |
donepezil | Phase 2 | Alzheimer's Disease | - |
Depatuxizumab mafodotin | Phase 2 | Glioblastoma | - |
Darigabat | Phase 2 | Panic Disorder | - |
elezanumab | Phase 2 | Multiple Sclerosis (MS) | - |
AGN-151597 | Phase 2 | Advanced Retinitis Pigmentosa | - |
Gemcitabine | Phase 2 | Urothelial Carcinoma | - |
Etoposide | Phase 2 | Small Cell Lung Cancer | - |
0.5 mg estradiol / 0.1 mg norethindrone acetate | Phase 2 | Heavy Uterine Bleeding | - |
ABBV-3373 | Phase 2 | Rheumatoid Arthritis (RA) | - |
ABBV-453 | Phase 2 | Multiple Myeloma | - |
AGN-242428 | Phase 2 | Dry Eye Disease | - |
CVL-865 | Phase 2 | Seizures | - |
Eluxadoline | Phase 2 | Irritable Bowel Syndrome | - |
ABBV-668 | Phase 2 | Ulcerative Colitis | - |
Risankizumab 600 mg IV | Phase 2 | Crohn Disease | - |
Pneumococcal 13-valent conjugate vaccine (PCV-13) | Phase 2 | Rheumatoid Arthritis | - |
Ravagalimab 600 mg | Phase 2 | Ulcerative Colitis (UC) | - |
Panitumumab | Phase 2 | Metastatic Colorectal Cancer | - |
ABBV-383 (Etentamig) | Phase 2 | Immunoglobulin Light Chain (AL) Amyloidosis | - |
AGN-151607 | Phase 2 | Post-Operative Atrial Fibrillation | - |
Leuprorelin Acetate Depot | Phase 2 | Endometriosis | - |
Daratumumab | Phase 2 | Multiple Myeloma | - |
ABBV-932 | Phase 2 | Generalized Anxiety Disorder (GAD) | - |
AGN-193408 SR | Phase 2 | Open-angle Glaucoma | - |
ABT-414 | Phase 2 | Malignant Glioma | - |
MEDI0618 | Phase 2 | Migraine | - |
ABT-719 | Phase 2 | Acute Kidney Injury | - |
ABBV-706 | Phase 2 | Small Cell Lung Cancer | - |
Ombitasvir/ABT-450/Ritonavir | Phase 2 | Chronic Hepatitis C | - |
ABT-126 | Phase 2 | Schizophrenia | - |
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) | Phase 2 | Endometriosis | - |
Topical Steroid | Phase 2 | Diabetic Retinopathy (DR) | - |
ABT-199 | Phase 2 | Acute Myelogenous Leukemia | - |
ABT-072 | Phase 2 | Hepatitis C Virus Infection | - |
Icalcaprant | Phase 2 | Major Depressive Disorder | - |
Regulatory & News
Approvals, filings, and latest developments